Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: A randomized phase III study (ALLY-3+) | HCV Guidance

HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C

Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: A randomized phase III study (ALLY-3+)

Leroy V, Angus P, Bronowicki JP, et al. Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: A randomized phase III study (ALLY-3+). Hepatology. 2016 Mar 4.th ed. 2016;63(5):1430-1441.

Publication Type:

Journal Article

Authors:

Vincent Leroy; Angus, P.; Bronowicki, JP.; et, al

Source:

Hepatology, Volume 63, Issue 5, p.1430-1441 (2016)

Notes:

PMID: 26822022

Cited On:

HCV Resistance Primer

Export Citation:

RIS Format

Top